Abstract
Second-generation antipsychotics have been growingly implicated in the acute and maintenance treatment for bipolar affective disorder (BAD). Risperidone long-acting injection (LAI) has been the first second-generation depot indicated for its maintenance treatment. However, its long-term motor side-effects, especially tardive dyskinesia (TD), has not been commonly reported or studied. The case reported here a bipolar patient with atypical presentation of TD involving only the crico-hyoid region of the neck associated with the use of risperidone LAI in adjunct to lithium and sodium valproate as maintenance therapy.
Keywords: Risperidone long-acting injection, bipolar, maintenance, tardive dyskinesia, crico-hyoid region
Current Drug Safety
Title:Atypical Presentation of Tardive Dyskinesia Associated with Risperidone Long-Acting Injection as Maintenance Treatment in Bipolar Affective Disorder: A Case Report
Volume: 7 Issue: 1
Author(s): Albert K.K. Chung
Affiliation:
Keywords: Risperidone long-acting injection, bipolar, maintenance, tardive dyskinesia, crico-hyoid region
Abstract: Second-generation antipsychotics have been growingly implicated in the acute and maintenance treatment for bipolar affective disorder (BAD). Risperidone long-acting injection (LAI) has been the first second-generation depot indicated for its maintenance treatment. However, its long-term motor side-effects, especially tardive dyskinesia (TD), has not been commonly reported or studied. The case reported here a bipolar patient with atypical presentation of TD involving only the crico-hyoid region of the neck associated with the use of risperidone LAI in adjunct to lithium and sodium valproate as maintenance therapy.
Export Options
About this article
Cite this article as:
K.K. Chung Albert, Atypical Presentation of Tardive Dyskinesia Associated with Risperidone Long-Acting Injection as Maintenance Treatment in Bipolar Affective Disorder: A Case Report, Current Drug Safety 2012; 7 (1) . https://dx.doi.org/10.2174/157488612800492807
DOI https://dx.doi.org/10.2174/157488612800492807 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Colchicine Protects Dopaminergic Neurons in a Rat Model of Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Evaluating Drug Safety in Children and Adolescents with Bipolar Disorder
Current Drug Safety Membrane Pathology in Schizophrenia: Implication for Arachidonic Acid Signaling
Current Medicinal Chemistry - Central Nervous System Agents Ginkgo biloba as an Alternative Medicine in the Treatment of Anxiety in Dementia and other Psychiatric Disorders
Current Drug Metabolism Monoamine Oxidase-B (MAO-B) Inhibitors in the Treatment of Alzheimer’s and Parkinson’s Disease
Current Medicinal Chemistry Possible Targets of Herbals for Type 3 Diabetes: A Review
Current Traditional Medicine Effects of Eugenol on the Central Nervous System: Its Possible Application to Treatment of Alzheimers Disease, Depression, and Parkinsons Disease
Current Bioactive Compounds Mitochondrial Disturbances, Tryptophan Metabolites and Neurodegeneration: Medicinal Chemistry Aspects
Current Medicinal Chemistry Improving Red Blood Cell K-Uptake and its Impact on O2/CO2 Exchange, and NO-Generation in Microvascular CHD: A Novel Therapeutic Approach
Recent Patents on Cardiovascular Drug Discovery The GNAS Locus: Quintessential Complex Gene Encoding Gsα, XLαs, and other Imprinted Transcripts
Current Genomics Role of the Central Cholinergic System in the Therapeutics of Schizophrenia
Current Neuropharmacology Anti-NMDA Receptor Encephalitis: Efficacy of Treatment for Male Patients and miRNA Biomarker
Current Medicinal Chemistry Drugs as Possible Triggers of Takotsubo Cardiomyopathy: A Comprehensive Literature Search - Update 2015
Current Clinical Pharmacology Subject Index To Volume 7
Current Drug Targets Neurokinin Peptides and Neurokinin Receptors as Potential Therapeutic Intervention Targets of Basal Ganglia in the Prevention and Treatment of Parkinsons Disease
Current Drug Targets Artificial Neural Network (ANN) Based Modelling for D1 Like and D2 Like Dopamine Receptor Affinity and Selectivity
Medicinal Chemistry Anti-Oxidants in Parkinson’s Disease Therapy: A Critical Point of View
Current Neuropharmacology Alpha-synuclein, Proteotoxicity and Parkinson's Disease: Search for Neuroprotective Therapy
Current Neuropharmacology Anti-Parkinsonian Effects of Nurr1 Activator in Ubiquitin-Proteasome System Impairment Induced Animal Model of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Major Developments in the Design of Inhibitors along the Kynurenine Pathway
Current Medicinal Chemistry